San Diego, CA, United States of America

Tetsuo Uno

USPTO Granted Patents = 26 

 

 

Average Co-Inventor Count = 6.5

ph-index = 8

Forward Citations = 257(Granted Patents)


Company Filing History:

goldMedal16 out of 3,923 
 
Novartis Ag
 patents
silverMedal10 out of 151 
 
Irm LLC
 patents
bronzeMedal1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2008-2024

Loading Chart...
Loading Chart...
Loading Chart...
26 patents (USPTO):

Title: Tetsuo Uno: A Notable Innovator in Antibody Drug Conjugates

Introduction

Tetsuo Uno is a prominent inventor based in San Diego, California, known for his significant contributions to the field of biotechnology and pharmaceuticals. With an impressive portfolio of 26 patents, Uno's work primarily focuses on innovative antibody drug conjugates that have the potential to revolutionize cancer treatment.

Latest Patents

Among his latest patents, Uno's work on "Anti-CCR7 antibody drug conjugates" stands out. This application discloses anti-CCR7 antibodies and their antigen-binding fragments, along with antibody drug conjugates. The invention extends to methods for treating or preventing cancer using these antibodies, which can also serve as diagnostic reagents.

Another noteworthy patent is the development of "Antibody drug conjugates for ablating hematopoietic stem cells." This invention features antibody drug conjugates that link specifically to human cKIT, with the capability to ablate hematopoietic stem cells in patients requiring such treatment. These advancements offer promising pharmaceutical compositions that enhance therapeutic outcomes for patients.

Career Highlights

Tetsuo Uno has amassed a distinguished career, working with esteemed organizations such as Novartis AG and Irm LLC. His professional journey has been marked by his commitment to developing innovative solutions that address critical medical challenges.

Collaborations

Throughout his career, Uno has collaborated with notable colleagues like Yunho Jin and Bernhard Hubert Geierstanger, further contributing to the advancement of research and development in the biopharmaceutical sector. These partnerships have facilitated the exchange of ideas and enabled the pursuit of groundbreaking innovations.

Conclusion

In conclusion, Tetsuo Uno's contributions to antibody drug conjugates have positioned him as a key figure in the innovation landscape of cancer treatment. His 26 patents reflect a dedicated pursuit of scientific advancement, promising better therapeutic options for patients in need. As the field of biotechnology continues to evolve, Uno's work will likely play an essential role in shaping the future of medical therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…